secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptiNose, Inc. (—)
CIK:        0001494650
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001494650-24-000061
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 3.03, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptiNose raises $55M in registered direct offering; posts preliminary Q1 2024 revenue of $14.9M
--------------------------------------------------------------------------------

- Raises ~$55M via 31.8M shares at $1.00 and 23.7M pre-funded warrants at $0.999; led by Nantahala Capital and D.E. Shaw.
- Preliminary Q1 2024: net XHANCE revenue ~$14.9M, op ex ~$21.7M, net loss ~$14.1M, cash $51.6M.
- FY2024 guidance: XHANCE net revenue $85-95M, avg net revenue per Rx >$230 (prior >$220), total GAAP op ex $95-101M.
- Debt amendment: waives going concern qualification for FY2024; reduces minimum cash to $20M after Sep 2025; issues 4.68M shares to Pharmakon for fees.
- Exercise price of Nov 2022 warrants reduced from $2.565 to $1.00; Pharmakon warrants to $1.00, extended to Nov 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000061/0001494650-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000061/optn-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001494650-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer